SAN CARLOS, Calif.--(BUSINESS WIRE)--Natus Medical Incorporated (Nasdaq:BABY) today announced that the FDA has approved its supplement to the premarket approval application for the Olympic Cool-Cap. Natus is now cleared to resume shipping the device within the United States. The Cool-Cap is the only FDA-approved device for the treatment of hypoxic ischemic encephalopathy (“HIE”) in term newborns. The system provides selective head cooling to prevent or reduce the severity of neurologic injury associated with HIE.
